The present invention relates to cardiovascular event in a patient with type 2 diabetes. In a cross-sectional study population of 672 participants with T2D, the inventors demonstrated that the risk of CV events, evaluated by coronary artery calcium (CAC) score, is positively associated with blood leukocyte and monocyte counts. Then, considering frequencies of the 3 monocyte subtypes, they propose 3 endotypes of participants with T2D differing in blood monocyte counts, classical monocyte frequency (CD45+ CD14++ CD16-) and the risk of CV events. The predictive association between monocyte count and major adverse cardiovascular events (MACE) was validated through an independent prospective T2D cohort. In fact, monocyte count increase was associated with a statistically significant 2.8-fold increase of MACE and a 5.1-fold increased risk of CV deaths. T2D participants with median monocyte count > 0.5 x 109/L, suffered significantly more MACE. Thus, the invention relates to a method of determining whether a patient with a type 2 diabetes (TD2) is at a risk of developing a cardiovascular event.